1. Home
  2. OLP vs LYEL Comparison

OLP vs LYEL Comparison

Compare OLP & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo One Liberty Properties Inc.

OLP

One Liberty Properties Inc.

HOLD

Current Price

$22.94

Market Cap

508.4M

Sector

Real Estate

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$23.47

Market Cap

556.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OLP
LYEL
Founded
1982
2018
Country
United States
United States
Employees
N/A
161
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
508.4M
556.1M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
OLP
LYEL
Price
$22.94
$23.47
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$26.75
$30.60
AVG Volume (30 Days)
69.8K
74.3K
Earning Date
05-05-2026
05-12-2026
Dividend Yield
7.85%
N/A
EPS Growth
N/A
N/A
EPS
1.15
N/A
Revenue
$82,740,000.00
$36,000.00
Revenue This Year
$11.98
N/A
Revenue Next Year
$3.71
$16,285.34
P/E Ratio
$19.93
N/A
Revenue Growth
1.02
N/A
52 Week Low
$19.62
$0.39
52 Week High
$25.90
$45.00

Technical Indicators

Market Signals
Indicator
OLP
LYEL
Relative Strength Index (RSI) 59.33 55.08
Support Level $22.11 $21.27
Resistance Level $23.38 $27.30
Average True Range (ATR) 0.46 1.71
MACD 0.12 0.43
Stochastic Oscillator 91.16 74.68

Price Performance

Historical Comparison
OLP
LYEL

About OLP One Liberty Properties Inc.

One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: